Abstract. We examined the gene expression profiles of esophageal squamous cell carcinomas (ESCCs) with respect to degree of invasive depth and lymph node (LN) involvement in a large cohort. We used high-density oligonucleotide microarrays to examine the expression of 22,115 genes in 54 ESCCs and 11 non-cancerous esophageal tissues. We found that 4,155 genes were biologically significant in both ESCC and non-cancerous esophageal tissue by analysis of Present Call (hybridization quality by Affymetrix) throughout all samples. From these genes, we used a supervised learning method to select genes responsible for the development of ESCC. We found that 999 genes were expressed differentially in pT1/pN0 tumors vs. non-cancerous esophageal tissue. In the same manner, 48, 66 and 30 genes were expressed differentially in pT1/pN0 tumors vs. pT1/pN1 tumors, pT1/pN0 tumors vs. pT2-4/ pN0 tumors and pT2-4/pN0 tumors vs. pT2-4/pN1 tumors, respectively. Intriguingly, there were no overlaps between the 48 LN metastasis-related genes of pT1 tumors and the 30 LN metastasis-related genes of pT2-4 tumors, suggesting that ESCCs with distinct invasive depths express different genes linked to LN metastasis. Our present results suggest that the degree of invasive depth must be considered when predicting LN metastasis of ESCC from gene expression profiles.
Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most fatal malignancies in the world because progression occurs without symptoms and many patients are malnourished at the time of diagnosis (1, 2) . It is well known that lymph node (LN) metastasis correlates with a poor outcome for ESCC patients (3) . In treatment of advanced ESCC with LN metastasis, surgery remains the best palliation for patients; however, the 5-year survival rate is ~20% (4) . This poor outcome may be explained in part by the fact that it remains unclear how LN metastasis develops and which genes are involved in the process. Tumorigenesis is a complex, multistage process that involves many genes. Therefore, analysis of gene expression patterns in ESCC is necessary in order to develop diagnostic, prognostic and therapeutic tools to improve outcome.
DNA microarrays have been used to comprehensively analyze many genes involved in the pathogenesis of various malignancies (5) . This technology has made it possible to predict the cancer outcome accurately (6, 7) .
With respect to ESCC, there have been many DNA microarray studies identifying genes related to pathogenesis or therapy of ESCC (8) (9) (10) (11) (12) (13) (14) (15) (16) ; however, only two studies considered and analyzed LN metastasis (17, 18) . Kan et al (17) reported that molecular profiling of 60 genes accurately predicted LN metastasis in 10 of 13 (77%) ESCCs. Molecular profiling by Tamoto et al (18) correctly predicted LN metastasis in 16 of 18 (89%) ESCCs. However, in these studies (17, 18) , the number of samples tested was too small to validate the predictive performance or to clarify the molecular basis of LN metastasis. To resolve these issues, molecular profiling of a larger number of samples is needed.
In the present study, we used high-density oligonucleotide microarray to identify LN metastasis-related genes in a large number of ESCC (n=54) and non-cancerous esophageal tissues (n=11). We focused in particular on the relation between invasion depth and LN metastasis and then classified the ESCC samples into four different tumor classes according to degree of invasive depth (pT1 vs. pT2-4) and the presence or absence of LN metastasis (pN0 vs. pN1). We used our original supervised learning method (19) (20) (21) (22) (23) to compare genes whose expression differed significantly between the four tumor classes and the non-cancerous tissue. Our gene expression profiles provide new insights into the mechanisms underlying carcinogenesis and progression of ESCC, particularly LN metastasis.
Materials and methods
Patients. Fifty-four patients underwent surgical treatment for ESCC at Yamaguchi University Hospital between September 1997 and March 2003; none had undergone prior chemotherapy or radiotherapy. Preoperative imaging analysis revealed that no patient had distant metastases at the time of surgery. Written informed consent was obtained from all patients prior to surgery. The study protocol was approved by the Institutional Review Board for the Use of Human Subjects at the Yamaguchi University School of Medicine. All ESCC was diagnosed histopathologically by at least two trained pathologists. Tumor stage and grade were classified according to the pTNM Classification of the International Union Against Cancer (24) . Eleven nontumorous esophageal samples from 11 patients who underwent esophageal resection and who had histologically normal esophageal mucosa were included as control.
DNA microarray analysis. Each cancer tissue sample was divided into two specimens; one part was frozen in liquid nitrogen immediately after surgical resection, and the other part was used for histopathological examination. The clinical and pathologic data for these patients are summarized in Table I . RNA extractions, cDNA and cRNA syntheses and oligonucleotide microarray screening were performed as described previously with minor modifications (6, 19) . In the present study, we used the Human Genome U133 A ® DNA microarray chip (Affymetrix, Santa Clara, CA), which contains 22,115 genes.
Digitized image data from the microarray chip were processed using Affymetrix ® Microarray Suite 5.0 software, and initial absolute analysis was performed without scaling. For comparative analyses using Roche Affymetrix Chip Experiment-Analysis (RACE-A) software, the average fluorescence intensity of all the genes on each chip was set to 1000. We then used the average difference of the hybridization signal, which measures the mean difference in fluorescence intensity between a perfect match and centrally mismatched oligonucleotides of a probe set.
Gene selection. We first selected genes that had all present call (arbitrary units by Affymetrix) in all 54 ESCC samples and 11 non-tumorous esophageal mucosa samples. This filtering resulted in the identification of 4,155 genes (18.8%) of the 22,115 genes. We then profiled genes among noncancerous esophageal tissues and the four classes of ESCC (Fig. 1) . We used the Fisher ratio (6, (19) (20) (21) (22) (23) to evaluate the abilities of the selected genes to discriminate non-cancerous esophageal tissue (n=11) and pT1/pN0 tumors (n=9), pT1/ pN0 tumors and pT1/pN1 tumors (n=10), pT1/pN0 tumors and pT2-4/pN0 tumors (n=7), and pT2-4/pN0 tumors and pT2-4/pN1 tumors (n=28).
Results
To examine changes in gene expression in ESCC related to different clinicopathological characteristics, we performed Table I . Clinicopathological features. 
, well-differentiated tumor; G2, moderately-differentiated tumor; G3, poorly-differentiated tumor by TNM classification (24) . NS, not significant. Figure 1 . Schematic carcinogenesis and progression of ESCC. We classified the 65 esophageal tissues into five groups on the basis of tumor invasive depth and LN involvement, and then compared gene expression variations between groups using our original supervised learning theory (see Materials and methods). microarray analysis of 22,115 and found that 4,155 were differentially expressed in ESCC. For each comparison, we ranked the identified 4,155 genes in order of decreasing magnitude of the Fisher ratio. To determine the number of genes that should be considered, we performed a random permutation test as described previously (19) (20) (21) (22) (23) . From the distribution of the Fisher ratios based on the randomized data, we selected all genes that passed the random permutation test (P<0.01). We found that the levels of expression of 999 genes with Fisher ratios greater than 1.54 differed significantly between pT1/pN0 tumors and non-cancerous Tables II-V and  Fig. 2 show the 30 genes with the highest Fisher ratios in each comparison. These genes had various biological functions.
Interestingly, there were no overlaps between the 48 LN metastasis-related genes of pT1 tumors and the 30 LN meta- Table II . Top 30 genes whose expression levels differed between non-cancerous tissue and pT1 tumors without lymph node metastasis. 
Fold change, average of pT1 tumors without lymph node metastasis/non-cancerous tissue. Accession nos. and abbreviations were obtained from the URL website (http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene).
stasis-related genes of pT2-4 tumors, suggesting that ESCCs with distinct invasive depths have different genetic pathways linked to LN metastasis.
Discussion
Despite recent surgical improvements, the prognosis of ESCC patients remains poor, with a 5-year survival rate of ~20% (4). LN metastasis is one factor that strongly affects the outcome of ESCC (3). It was also reported that the degree of invasive depth of a tumor is closely related to LN metastasis in ESCC (25) . In the present study, to elucidate the molecular basis of LN metastasis of ESCC, we examined gene expression patterns from two viewpoints: invasion depth of tumor and LN metastasis. We found that pT1 ESCCs and pT2-4 ESCCs do not commonly express any genes linked to LN metastasis (supplementary Tables). This result suggests that prediction of LN metastasis of ESCC on the basis of expression profiles is limited unless we consider the depth of tumor invasion. This concept is supported by the results of previous studies in which molecular profiling misclassified the presence or absence of LN metastasis in 3 (23%) of 13 ESCCs (17) and 2 (11%) of 18 Table III . Top 30 genes whose expression levels differed between pT tumors without lymph node metastasis and pT1 tumors with lymph node metastasis. 
Fold change, average of pT1 tumors with lymph node metastasis/pT1 tumors without lymph node metastasis. Accession nos. and abbreviations were obtained from the URL website (http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene). (18) . Thus, in conjunction with our present finding, we propose that predictors for LN metastasis in ESCC should be established separately according to tumor invasion depth (pT1 and pT2-4) to obtain high predictive ability in a large cohort.
It is clinically important to accurately predict LN metastasis in pT1 ESCC to avoid unnecessary treatment of patients who have been cured by resection alone. In addition, elucidating the molecular basis of LN metastasis in this type of ESCC may identify new therapeutic targets. We found that the levels of 25 of the top 30 genes were lower in pT1/N1 ESCC than in pT1/N0 ESCC and that these 25 down-regulated genes were involved in various biological function activities (Table III) . The five up-regulated genes included RPL36 and RPL13, both of which are structural components of ribosomes. It was reported that the levels of expression of many RPL family genes were altered in ESCC cells showing acquired resistance to the anti-cancer agent cisplatin (12) . Thus, it is possible that both RPL36 and RPL13 may be involved in LN metastasis of pT1 ESCC.
No angiogenesis-related genes showed differential expression when we compared pT1/pN0 ESCC and pT1/ pN1 ESCC. In contrast, expression levels of VEGF were Table IV . Top 30 genes whose expression levels differed between pT1 tumors without lymph node metastasis and pT2-4 tumors without lymph node metastasis. 
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Fold change, average of pT2-4 tumors without lymph node metastasis/pT2-4 tumors with lymph node metastasis. Accession nos. and abbreviations were obtained from the URL website (http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene).
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significantly higher in pT2-4/pN0 ESCC than in pT2-4/pN1 ESCC (Table V) . It was reported that VEGF expression correlates with outcome and LN metastasis in ESCC (26) . Interestingly, the percentage of VEGF-positive cells appears to increase with the invasive depth of ESCC (27) . These reports support our finding that VEGF is related to LN metastasis in pT2-4 ESCC but not in pT1 ESCC. In the present study, we also identified NOTCH2 as a gene responsible for LN metastasis of pT2-4 ESCC. Recent evidence shows that Notch signaling from tumor cells can activate endothelial cells and trigger tumor angiogenesis both in vitro and in a xenograft mouse tumor model and that selective interruption of Notch signaling within tumors may have anti-angiogenic effects (28) . Collectively, these findings suggest that both VEGF and Notch play important roles in LN metastasis of pT2-4 ESCC via altered angiogenesis.
We found that 999 genes were expressed differentially between pT1/pN0 ESCC and non-cancerous esophageal tissue, this number of genes was much larger than that from other comparisons between tumor classes, suggesting that the levels of many genes (999/4,155, 24%) change drastically during carcinogenesis. Several studies have examined the expression Table V . Top 30 genes whose expression levels differed between pT2-4 tumors without lymph node metastasis and pT2-4 tumors with lymph node metastasis. 
Fold change, average of pT2-4 tumors with lymph node metastasis/pT2-4 tumors without lymph node metastasis. Accession nos. and abbreviations were obtained from the URL website(http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene). of carcinogenesis-related genes in ESCC (8) (9) (10) ; however, all of these studies compared non-cancerous esophageal samples with heterogeneous ESCC samples consisting of pT1 to pT4 tumors with or without LN metastasis, resulting in a failure to identify key genes. Recently, it was reported that the number of differentially expressed genes dramatically increased in a step-by-step fashion from normal esophageal epithelium to papilloma, dysplasia and invasive carcinoma in a rat ESCC model (15) . Because our present cohort did not include preneoplastic lesions such as papilloma and dysplasia, further studies are needed to identify genes with expression that differs between pre-neoplastic and non-cancerous esophageal tissues.
Among the 30 genes with differential expression between pT1/pN0 ESCC and non-cancerous esophageal tissues, increased expression of ubiquitination-related genes (PSMB3, PSMB4, PSMD2 and PSMD11) was the most characteristic gene signature (Table II) . It was reported that levels of PSMB3 are increased in breast cancer (29) . However, to our knowledge, there are no reports of up-regulation of expression of PSMB4, PSMD2, or PSMD11 in cancer. The ubiquitin pathway plays a central role in the regulation of cell growth and cell proliferation by degrading tumor suppressor proteins (30) and controlling the levels of key cell cycle proteins (31) , suggesting that increased levels of ubiquitination-related genes may account for some growth advantage to cancer cells. Thus, the four genes described here may be molecular targets for prevention or treatment of ESCC.
In the present study, DNA microarray analysis revealed that many genes are involved in carcinogenesis and progression of ESCC. We also found that pT1 ESCC and pT2-4 ESCC express no common genes responsible for LN metastasis, raising the difficulty of accurate prediction of LN metastasis in ESCC without also considering tumor invasion depth. Further studies are needed to clarify whether this strategy can be used to predict LN metastasis in other types of cancer in the alimentary tract. Supplementary Table I . Top 100 genes whose expression levels differed between non-cancerous tissue and pT1 tumors without lymph node metastasis. 
